Navigation Links
Favrille Announces Results from Phase 3 Registration Trial of Specifid in Patients with Follicular B-Cell Non-Hodgkin's Lymphoma
Date:5/27/2008

open to both treatment-naive and previously treated patients, ultimately enrolling a much larger treatment-naive population (78%). Patients were randomized at a one-to-one ratio to receive either Specifid or placebo following a standard course of Rituxan. The trial was conducted at 67 centers in the U.S.

Conference Call and Webcast

Favrille's management team will host a conference call today at 8:30 a.m. Eastern Time to discuss the information contained in this press release. A live audio webcast will be available on the Investor Relations section of the Company's web site at http://www.favrille.com . Alternatively, callers may participate in the conference call by dialing (866) 831-6267 or (617) 213-8857, passcode 99549869. A telephone replay of the call will also be available for 48 hours. The telephone replay can be accessed by dialing (888) 286-8010 or (617) 801-6888, passcode 20389415.

About Favrille, Inc.

Favrille, Inc. is a biopharmaceutical company focused on the development and commercialization of targeted immunotherapies for the treatment of cancer and other diseases of the immune system.

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to Favrille's product candidates, proprietary technologies and research and clinical development programs. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Favrille's actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, risks and uncertainties related to Favrille's ability to continue its operations, conserve cash or recognize value on our assets and additional risks discussed in Favrille's filings with the Securiti
'/>"/>

SOURCE Favrille, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Favrille Reports First Quarter 2008 Financial Results
2. Favrille to Host Conference Call and Live Webcast to Discuss First Quarter 2008 Financial Results on May 8, 2008
3. Favrille Reports Fourth Quarter and Year End 2007 Financial Results
4. Favrille Announces $21.1 Million Registered Direct Offering
5. Favrille to Present at BIOCOM Investor Conference, Acumen BioFin Rodman & Renshaw Healthcare Conference and CIBC World Markets Healthcare Conference
6. Favrille to Host Conference Call and Live Webcast to Discuss Third Quarter 2007 Financial Results on October 25, 2007
7. Favrille to Present at BIO InvestorForum
8. Favrille to Present at AG Edwards Emerging Growth Conference and Wall Street Analyst Forum
9. Favrille CEO to Present at Bear Stearns Healthcare Conference
10. Favrille CEO to Present at NewsMakers in the Biotech Industry Investment Conference
11. Dragon Pharma Announces June 26, 2008 for 2008 Annual Shareholders Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... CHARLOTTESVILLE, Virginia , September 2, 2015 ... sponsoring of the winners of the 2015 BeHEARD science ... Institute that offers rare disease researchers, access to the ... will use its drug repositioning and pathway analytics capability ... at Wylder Nation Foundation in the study of Niemann-Pick ...
(Date:9/2/2015)... 2, 2015 Aytu BioScience, Inc. (OTCQB: AYTU), ... urological and related conditions, announced today that it has ... convertible note financing, raising a total of $5.175 million, ... million. Josh Disbrow , Chief ... placement are intended to be used to conduct clinical ...
(Date:9/2/2015)... CHARLOTTESVILLE, Virginia , September 2, 2015 /PRNewswire/ ... Sponsoring der Gewinner des Wettbewerbs BeHEARD von 2015 ... einen internationalen vom Rare Genomics Institute. ... Wirksamkeit von Medikamenten für die Behandlung anderer Krankheiten ... wurde, Steven Laffoon und sein Team ...
(Date:9/2/2015)... San Diego, CA (PRWEB) , ... September 02, ... ... from troubleshooting faults in manufacturing equipment, to creating professional commercial video content, to ... beautifully detailed views of fascinating events that go by too quickly to process ...
Breaking Biology Technology:Biovista Sponsors Wylder Nation Foundation's Research on Acid Sphingomyelinase Deficiency 2Aytu BioScience Completes $5.175 Million Private Placement 2Aytu BioScience Completes $5.175 Million Private Placement 3Biovista sponsert die Forschung von Wylder Nation Foundation zum Thema Mangel an saurer Sphingomyelinase 2Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 2Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 3
... ALTO, Calif., Oct. 24 Jazz,Pharmaceuticals, Inc. (Nasdaq: ... quarter 2007 financial results on Tuesday, November 6, 2007,following ... host an investor conference call and live audio webcast ... 6, 2007, at 5:00 p.m.,Eastern Time/2:00 p.m. Pacific Time. ...
... Help Millions Suffering ... from Painful Sex, WASHINGTON, Oct. ... Practice, a young woman unable to have sex with her,new husband, visits ... screams in pain and is diagnosed with,vulvodynia. With the help of Hollywood ...
... PALO ALTO, Calif., Oct. 24 Vivo Ventures, a ... that,James Huang will join the firm as an Executive ... Mr. Huang will,work with Vivo,s portfolio companies while enhancing ... James coming on board and what he will be ...
Cached Biology Technology:Jazz Pharmaceuticals, Inc. to Announce Third Quarter 2007 Financial Results on November 6, 2007 2ABC's 'Private Practice' Inaccurately Portrays Serious Women's Health Condition 2Vivo Ventures Expands Team with the Addition of James Huang as an Executive in Residence 2
(Date:8/20/2015)... 2015 The wearable technology market has ... and healthy. However, wearable technology has the potential ... help improve diagnostic capabilities and therapeutic outcomes. Today, ... Wearable Technologies Conference 2015 , where Barrett ... in healthcare.    "Over the past ...
(Date:8/18/2015)... , Aug. 18, 2015  Navitas today ... contributor to the Submission Content Management webinar ... a non-profit forum. Dedicated to the Implementation of ... neutral platform for industry, vendors, health authorities, ... and work towards a standard method of ...
(Date:8/12/2015)... , August 12, 2015 ... of mobile payment innovation and advanced biometrics technology is ... the way consumers rely on using their credit cards, ... reinventing the future for payment services led by companies ... NXTD ), :  Google, Inc. (NASDAQ: GOOG ), ...
Breaking Biology News(10 mins):Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6
... suggests that monoclonal antibody therapy of cancer can be improved ... a researcher at Georgetown University Medical Center,s Lombardi Comprehensive Cancer ... . "We believe that antibody therapy has the capacity ... of the cancer center at GUMC and an internationally recognized ...
... another on the reef, they have two options: merge into ... for space. Now, a report in the March 19th ... gene that may help to decide that fate. "We ... recognizes a member of its own species based on cell-cell ...
... Improved technology, partnerships and collaboration across two provinces ... the use of eye-movement tests that help identify ... (FASD). "Our initial study was carried out ... had to travel to Queen,s to participate in ...
Cached Biology News:Lombardi research: Monoclonal antibodies primed to become potent immune weapons against cancer 2Lombardi research: Monoclonal antibodies primed to become potent immune weapons against cancer 3Gene decides whether coral relative will fuse or fight 2Fetal alcohol syndrome testing expands 2
...
Ethylene glycol-bis(2-aminoethyl ether)-N,N,N',N'-tetraacetic acid...
... efficiencies and the chemistry of light production ... benefit that they require simple triggering conditions ... This benefit has been exploited to great ... compounds can also be easily modified to ...
Required to perform reference file generation, flatfield calibration and performance verification processes on the GSD-501...
Biology Products: